NCT03541772View on ClinicalTrials.gov

Evaluation of Oncoxin-Viusid® in Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 20, 2015

Primary Completion Date

October 16, 2017

Study Completion Date

October 30, 2017

Conditions
Head Cancer Neck
Interventions
DIETARY_SUPPLEMENT

Oncoxin-Viusid®

Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments

DIETARY_SUPPLEMENT

Placebo

Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments

Trial Locations (1)

10400

National Institute of Oncology and Radiobiology of Cuba, Vedado

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03541772 - Evaluation of Oncoxin-Viusid® in Head and Neck Cancer | Biotech Hunter | Biotech Hunter